TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

M. Jasek, Lukasz Gondek, N. Bejanyan, R. Tiu, J. Huh, K. S. Theil, C. O'Keefe, M. A. McDevitt, J. P. MacIejewski

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)216-219
Number of pages4
Issue number1
Publication statusPublished - Jan 2010

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this